Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

Biothera's Phase II clinical trials in lung cancer attain stage 1 endpoint

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

Scientists identify novel small molecules that block human tumor cell growth

Scientists identify novel small molecules that block human tumor cell growth

Researchers pinpoint new approach that can treat pediatric leukemia

Researchers pinpoint new approach that can treat pediatric leukemia

Experts suggest Fukushima clean-up workers store blood cells for future use

Experts suggest Fukushima clean-up workers store blood cells for future use

Novel drug holds potential against resistant chronic myeloid leukemia

Novel drug holds potential against resistant chronic myeloid leukemia

Protest over planned cuts to Australian medical research funding

Protest over planned cuts to Australian medical research funding

CINJ experts to comment on vaccine therapy and biomedical informatics

CINJ experts to comment on vaccine therapy and biomedical informatics

NCI, ASH, AMEH join to improve care for patients with AML

NCI, ASH, AMEH join to improve care for patients with AML

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

Study reveals few genes involved with lymphoma shared by dogs and humans

Study reveals few genes involved with lymphoma shared by dogs and humans

Study: New cancer drug shrinks tumors in mouse model with few side effects

Study: New cancer drug shrinks tumors in mouse model with few side effects

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen launches InformThyroid, a panel of molecular markers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.